In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts.
BACKGROUND
The patency of AV expanded polytetrafluoroethylene (ePTFE) grafts for hemodialysis is impaired by intimal hyperplasia (IH) at the venous outflow tract. The absence of a functional endothelial monolayer on the prosthetic grafts is an important stimulus for IH. In the present study, we evaluated the feasibility of capturing endothelial progenitor cells in vivo using anti-CD34 antibodies on ePTFE grafts to inhibit IH in porcine AV ePTFE grafts.


RESULTS
In 11 pigs, anti-CD34-coated ePTFE grafts were implanted between the carotid artery and internal jugular vein. Bare ePTFE grafts were implanted at the contralateral side. After 3 (n=2) or 28 (n=9) days, the pigs were terminated, and the AV grafts were excised for histological analysis and SEM. At 3 and 28 days after implantation, 95% and 85% of the coated graft surface was covered by endothelial cells. In contrast, no cell coverage was observed in the bare graft at 3 days, whereas at 28 days, bare grafts were partly covered with endothelial cells (32%; P=0.04). Twenty-eight days after implantation, IH at the venous anastomosis was strongly increased in anti-CD34-coated grafts (5.96+/-1.9 mm2) compared with bare grafts (1.70+/-0.4 mm2; P=0.03). This increase in IH coincided with enhanced cellular proliferation at the venous anastomosis.


CONCLUSIONS
Autoseeding with anti-CD34 antibodies results in rapid endothelialization within 72 hours. Despite persistent endothelial graft coverage, IH at the outflow tract is increased profoundly at 4 weeks after implantation. Further modifications are required to stimulate the protective effects of trapped endothelial cells.
Rotmans
Joris I
JI
Laboratory of Experimental Cardiology, University Medical Center, Utrecht, The Netherlands.
Heyligers
Jan M M
JM
Verhagen
Hence J M
HJ
Velema
Evelyn
E
Nagtegaal
Machiel M
MM
de Kleijn
Dominique P V
DP
de Groot
Flip G
FG
Stroes
Erik S G
ES
Pasterkamp
Gerard
G
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D018952:Antigens, CD34 / Q000276:immunology; D001166:Arteriovenous Shunt, Surgical / Q000379:methods*; D001807:Blood Vessel Prosthesis / Q000009:adverse effects* / Q000592:standards; D004730:Endothelium, Vascular / Q000166:cytology* / Q000187:drug effects; D005260:Female; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000276:immunology; D006965:Hyperplasia / Q000209:etiology*; D011138:Polytetrafluoroethylene / Q000627:therapeutic use*; D006435:Renal Dialysis / Q000009:adverse effects / Q000295:instrumentation; D013552:Swine; D023822:Tissue Engineering / Q000379:methods; D017539:Tunica Intima / Q000187:drug effects / Q000473:pathology
D000911:Antibodies, Monoclonal; D018952:Antigens, CD34; D011138:Polytetrafluoroethylene